adrenocortical carcinoma (Cancer)
Information
- Disease name
- adrenocortical carcinoma
- Disease ID
- DOID:3948
- Description
- "An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has_material_basis_in abnormally proliferating cells derives_from epithelial cells." [url:http\://cancergenome.nih.gov/cancersselected/AdrenocorticalCarcinoma, url:http\://www.cancer.gov/cancertopics/types/adrenocortical]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04187404 | Active, not recruiting | Phase 1/Phase 2 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | July 23, 2020 | November 30, 2025 |
| NCT00568139 | Active, not recruiting | Evaluation of Side Effects of Mitotane | January 2008 | December 2024 | |
| NCT03333616 | Active, not recruiting | Phase 2 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | December 28, 2017 | May 31, 2025 |
| NCT02673333 | Active, not recruiting | Phase 2 | Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma | February 2016 | February 2025 |
| NCT04358107 | Active, not recruiting | Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) | April 20, 2020 | December 31, 2024 | |
| NCT00003038 | Completed | Phase 1 | Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors | October 1997 | January 2003 |
| NCT00436410 | Completed | Early Phase 1 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | December 2006 | August 2009 |
| NCT04373265 | Completed | Phase 1 | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) | September 30, 2020 | January 12, 2024 |
| NCT00445718 | Completed | Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging | July 2001 | January 2013 | |
| NCT00453895 | Completed | Phase 2 | Sunitinib in Refractory Adrenocortical Carcinoma | July 2007 | February 2012 |
| NCT00454103 | Completed | Phase 1/Phase 2 | Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy | March 2007 | February 2009 |
| NCT01833832 | Completed | Phase 2 | Surgery and Heated Chemotherapy for Adrenocortical Carcinoma | April 12, 2013 | August 9, 2018 |
| NCT01898715 | Completed | Phase 1 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | August 13, 2013 | October 17, 2017 |
| NCT02015026 | Completed | Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma | December 13, 2013 | March 2, 2018 | |
| NCT00436657 | Completed | Phase 1 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | February 2007 | April 2011 |
| NCT00324012 | Completed | Phase 2 | Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma | April 2006 | February 2012 |
| NCT00002608 | Completed | Phase 2 | Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | May 1994 | April 2005 |
| NCT05361083 | Completed | Early Phase 1 | First-in-human Evaluation of [18F]CETO | September 1, 2019 | February 28, 2022 |
| NCT00924989 | Completed | Phase 3 | A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma | December 1, 2009 | October 8, 2012 |
| NCT01048892 | Completed | Phase 1 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | September 2009 | |
| NCT01262235 | Completed | Phase 1/Phase 2 | A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients | December 2010 | August 2015 |
| NCT01514526 | Completed | Phase 2 | Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma | January 2012 | November 2016 |
| NCT01528956 | Completed | Studying Genes in Samples From Younger Patients With Adrenocortical Tumor | February 2012 | ||
| NCT05344027 | Completed | The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma | April 11, 2022 | March 1, 2023 | |
| NCT05036434 | Enrolling by invitation | Phase 2 | Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma | November 15, 2021 | August 31, 2026 |
| NCT03474237 | Enrolling by invitation | A Prospective Cohort Study for Patients With Adrenal Diseases | October 1, 2018 | December 31, 2027 | |
| NCT05839886 | Not yet recruiting | The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma | May 1, 2023 | December 1, 2024 | |
| NCT06333314 | Not yet recruiting | Phase 2 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | May 2024 | September 2030 |
| NCT05660889 | Recruiting | Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma | October 23, 2022 | December 31, 2024 | |
| NCT00453674 | Recruiting | German Adrenocortical Carcinoma Registry | January 2003 | December 2030 | |
| NCT00457587 | Recruiting | Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma | September 2005 | December 2026 | |
| NCT00669266 | Recruiting | Adrenal Tumors - Pathogenesis and Therapy | September 2002 | December 2030 | |
| NCT03050268 | Recruiting | Familial Investigations of Childhood Cancer Predisposition | April 6, 2017 | March 31, 2037 | |
| NCT03127774 | Recruiting | Phase 2 | Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma | September 22, 2017 | December 2025 |
| NCT03612232 | Recruiting | Phase 2 | Cabozantinib in Advanced Adrenocortical Carcinoma | June 4, 2019 | April 30, 2025 |
| NCT03746431 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | January 17, 2019 | June 2026 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT04318730 | Recruiting | Phase 2 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | June 12, 2021 | April 1, 2025 |
| NCT05563467 | Recruiting | Phase 2 | Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. | January 31, 2023 | May 31, 2027 |
| NCT05634577 | Recruiting | Phase 2 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | March 23, 2023 | January 1, 2028 |
| NCT05763524 | Recruiting | European Multicenter Study on Role of Lymph Node Dissection in Surgical Management of Adrenal Cortical Carcinoma | December 15, 2022 | September 2023 | |
| NCT05913427 | Recruiting | Phase 2 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) | June 8, 2022 | June 8, 2027 |
| NCT05999292 | Recruiting | Phase 1 | Phase 1 Study of 68Ga-R8760 | September 11, 2023 | April 2024 |
| NCT06050057 | Recruiting | Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy | September 3, 2023 | June 30, 2026 | |
| NCT06066333 | Recruiting | Phase 2 | Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma | September 27, 2023 | September 27, 2026 |
| NCT01832974 | Terminated | Phase 1 | Possible New Therapy for Advanced Cancer | December 2012 | September 2014 |
| NCT04447014 | Terminated | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) | June 25, 2020 | January 12, 2023 | |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT00002921 | Terminated | Phase 2 | S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery | March 1997 | January 2004 |
| NCT03145285 | Unknown status | Phase 2 | Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma | April 18, 2017 | April 18, 2021 |
| NCT02324647 | Unknown status | Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield | January 2015 | November 2022 | |
| NCT03257891 | Unknown status | Phase 2 | Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines | January 25, 2018 | January 24, 2022 |
| NCT03723941 | Unknown status | Phase 3 | Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma | July 1, 2018 | June 30, 2021 |
| NCT00777244 | Unknown status | Phase 3 | Efficacy of Adjuvant Mitotane Treatment (ADIUVO) | April 2008 | December 2020 |
| NCT00786110 | Unknown status | Phase 2 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients | April 2008 | October 2010 |
| NCT00469469 | Withdrawn | Phase 2 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | May 2007 | September 2009 |
- Disase is a (Disease Ontology)
- DOID:660
- Cross Reference ID (Disease Ontology)
- GARD:558
- Cross Reference ID (Disease Ontology)
- MESH:D018268
- Cross Reference ID (Disease Ontology)
- MIM:202300
- Cross Reference ID (Disease Ontology)
- NCI:C9325
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:255035007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206686
- Exact Synonym (Disease Ontology)
- Adrenal cortical carcinoma
- Exact Synonym (Disease Ontology)
- carcinoma of the Adrenal cortex
- HPO alt_id (Human Phenotype Ontology)
- HP:0002889
- HPO alt_id (Human Phenotype Ontology)
- HP:0006759
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006744
- OrphaNumber from OrphaNet (Orphanet)
- 1501
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018268